Autoimmune autonomic neuropathy is an immune-mediated disease, which can be associated with high titers of pathogenic antibodies to the nicotinic ganglionic acetylcholine receptor (gAChR).^[@R1][@R2][@R3]^ IV immunoglobulin (IVIg) is a commonly used treatment in autoimmune autonomic neuropathy associated with gAChR antibodies. Herein, we report a patient with an autonomic neuropathy associated with high-titer gAChR antibodies who developed selective pigmented hair loss while being treated with IVIg.

Methods {#s1}
=======

Standard protocol approvals, registrations, and patient consents {#s1-1}
----------------------------------------------------------------

The patient consented to the use of their medical records and image for this publication.

Case report {#s1-2}
-----------

A 34-year-old man with well-controlled type 1 diabetes (treated with an insulin pump), ulcerative colitis previously treated with colectomy, thyroiditis, and previous cerebellitis presented with the subacute onset of a severe pandysautonomia. Following an infectious illness, over the course of a few weeks, he developed light-headedness on standing, recurrent syncope, early satiety, bloating, difficulties emptying his bladder, erectile dysfunction, visual disturbance when transitioning from dark to light, dry eyes, and dry mouth. He received symptomatic treatment with oral fludrocortisone (0.1 mg twice daily) and midodrine (10 mg 3 times per day) and increased his fluid intake. He continued to have syncopal episodes weekly and was unable to ambulate due to symptomatic orthostasis requiring him to use a scooter. He had a pacemaker placed for bradycardia episodes. At the time of referral to our facility, 1 year after onset, his neurologic examination revealed a lying blood pressure of 145/102 with a pulse of 69 that dropped to 71/42 with a pulse of 72. His pupils were dilated and unreactive to light. Pinprick and vibration sensation were normal. He had stable mild ataxia as a residua of his previous cerebellitis. The remainder of the neurologic examination was normal. Autonomic testing revealed marked cardiovagal, cardiovascular adrenergic, and sudomotor abnormalities; a thermoregulatory sweat test showed global anhidrosis ([figure 1A](#F1){ref-type="fig"}). His serum gAChR antibodies were noted to be markedly elevated (titer, 1.47 nmol/L; normal, ≤0.02). He was diagnosed with an autoimmune autonomic neuropathy associated with gAChR antibodies; he also had mildly elevated glutamic acid decarboxylase 65 (titer, 0.43 nmol/L) and insulin (titer, 0.33 nmol/L) autoantibodies (normal range, 0--0.02 nmol/L) consistent with his history of autoimmune type 1 diabetes. He received 0.4 g/kg of IVIg once daily for 3 days, followed by once weekly for 6 weeks and every other week for 6 weeks. He had mixed white and black hair ([figure 2A](#F2){ref-type="fig"}), and after beginning his initial IVIg infusion, all dark hair fell out over 24--48 hours ([figure 2B](#F2){ref-type="fig"}). Diffuse alopecia areata (AA) was diagnosed. He reported a moderate improvement in his autonomic symptoms with IVIg and thus decided to continue IVIg, despite the dark hair loss coinciding with its use. Oral mycophenolate (1,000 mg twice daily) and pyridostigmine (60 mg 3 times daily) were added, and 1 year after initial assessment, autonomic testing and a repeat sweat test showed improvement ([figure 1B](#F1){ref-type="fig"}). He was transitioned to rituximab due to difficulty achieving therapeutic mycophenolate levels in the setting of his ileostomy. He remained without dark hair 5 years later.

![Thermoregulatory sweat test before and after treatment\
Thermoregulatory sweat test shows global anhidrosis (yellow) before IV immunoglobulin (IVIg) (A) with marked improvement (purple = normal sweating) after IVIg and pyridostigmine treatment (B).](NEURIMMINFL2019022483FF1){#F1}

![Selective dark hair loss\
The patient before (A) and after IV immunoglobulin treatment (B).](NEURIMMINFL2019022483FF2){#F2}

Discussion {#s2}
==========

This case was characteristic of an autoimmune autonomic neuropathy associated with high-titer gAChR antibodies.^[@R3]^ The rapid development of autonomic failure in the setting of well-controlled diabetes treated with an insulin pump, high-titer gAChR antibodies, and response to IVIg all suggested a primary diagnosis of an autoimmune autonomic neuropathy associated with gAChR antibodies, rather than a diabetic autonomic neuropathy.^[@R3]^ Strikingly, coinciding with his IVIg treatment, he developed acute selective dark hair loss ([figure 2](#F2){ref-type="fig"}) essentially turning his hair white overnight.

Historically, this syndrome of sudden whitening of hair has been termed "Marie Antoinette syndrome" after the hair of the Queen of France suddenly turned white when sentenced to execution during the French revolution.^[@R4]^ The pathogenesis of sudden whitening of hair is unknown, but diffuse AA has been proposed as the likely etiology given white hair lack follicular melanocytes, a suspected immune target in AA, potentially explaining selective dark hair loss.^[@R5],[@R6]^ An IVIg adverse effect was suspected given the temporal relationship and rare reports of alopecia with IVIg,^[@R7]^ although AA unrelated to IVIg was possible; our case was limited by absence of a scalp biopsy to assess for immunoglobulin deposition. The stress of the infusion and his autoimmune predisposition were other potential contributors to this intriguing phenomenon.^[@R6]^
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